CJ Bioscience, Inc. (KOSDAQ:311690)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,210.00
-260.00 (-3.07%)
At close: Mar 27, 2026
Market Cap107.27B -23.5%
Revenue (ttm)3.69B +6.5%
Net Income-24.00B
EPS-1,837.00
Shares Out13.07M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,814
Average Volume18,425
Open8,470.00
Previous Close8,470.00
Day's Range8,130.00 - 8,480.00
52-Week Range7,350.00 - 12,300.00
Beta0.45
RSI49.01
Earnings DateApr 2, 2026

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 311690
Full Company Profile

Financial Performance

In 2025, CJ Bioscience's revenue was 3.69 billion, an increase of 6.52% compared to the previous year's 3.47 billion. Losses were -24.00 billion, -26.90% less than in 2024.

Financial Statements